Atlanta 12/21/2013 4:00:00 AM
News / Finance

VistaGen Therapeutics (VSTA) Business Strategy Centers on Cutting-Edge Stem Cell Technology

MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company, focused on applying proprietary human pluripotent stem cell technology for drug rescue and cell therapy. Its Human Clinical Trials in a Test Tube is a pluripotent stem cell technology platform for predictive toxicology, drug development, and drug rescue.

In the company’s news,

VistaGen Therapeutics employs the expertise of company co-founder and renowned Canadian stem cell scientist Dr. Gordon Keller, as well as co-founder, president, and chief scientific officer Dr. Ralph Snodgrass.

Human Clinical Trials in a Test Tube™, the company’s human pluripotent stem cell (hPSC) technology platform, was developed using a combination of proprietary and exclusively licensed hPSC technologies, including those originating from two decades of research by Drs. Keller and Snodgrass.

The platform’s underlying technologies enable controlled differentiation of hPSCs into mature human cells specific to VistaGen’s current and potential predictive toxicology, drug metabolism, drug rescue, and regenerative cell therapy programs and commercial programs.

Utilizing these technologies, VistaGen is currently developing CardioSafe 3D™, a novel biological assay system that uses mature human heart cells derived from hPSCs to screen for heart toxicity in connection with the company’s drug rescue activities; LiverSafe 3D™, for predicting liver toxicity and metabolism issues in connection with the company’s drug rescue activities; and AV-101, a novel, orally available prodrug candidate focused on the treatment of neuropathic pain, depression, and potentially other neurological conditions.

VistaGen’s overarching goal is to combine its hPSC technology with medicinal chemistry to generate new, proprietary, chemical variants of small molecule drug candidates that were shelved due to unexpected heart or liver safety concerns.

The company believes its Human Clinical Trials in a Test Tube™ platform enables a more rapid and precise safety profile of drug rescue variants, allowing the company to generate a pipeline of drug rescue variants that it will license or sell to biotechnology and pharmaceutical companies that can further develop the products and bring them to market.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit

To connect with MissionIR via Facebook, please visit

To connect with MissionIR via Twitter, please visit

Please read FULL disclaimer on the MissionIR website:

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.